Skip to content
Erudio Health
menu
HCP commentary report · oncology · Not applicable · Interventional

SARON

SARON asks whether adding radical radiotherapy to systemic treatment helps patients with synchronous oligometastatic non-small cell lung cancer. Clinicians discuss patient selection, disease at diagnosis versus limited residual disease after induction, and comparisons with related randomized studies. Other topics include systemic-treatment era and sequencing, treatment of the lung primary, local treatment options, safety, patient-relevant endpoints, and potential implications for practice. SARON's main results are scheduled for ESMO 2026; this report reflects commentary before that presentation.

Non-small cell lung cancer
Inside this report

9 findings, and what sits behind each

titles and counts free

Select a finding to see what the full report holds for it: how many verified HCP statements and of what kind, the passages behind them, the sources and voices, and the counterview and limits it records.

Findings in the reportStatements
  1. Finding 1 of 9

    A negative local-therapy study was not interpreted uniformly as a verdict on synchronous oligometastatic disease

    statements
    11
    passages
    10
    sources
    2
    named voices
    4
    What the statements are
    Views 4Questions and uncertainty 4Clinical experience 0Comparisons 3Restated results and context 0
    How passages are used
    Supporting a statement 11Giving context 5
    Recorded with the finding
    • Counterview: recorded
    • Limitations: 3
    • Feeds the Medical Affairs question
    • 1 post or article
    • 1 podcast or video

    Draws on: Population and setting, The comparison, Primary endpoint: Overall Survival, Secondary endpoints.

    In the full report: the interpretation in full, all 11 statements cited to source and date, and the 2 sources linked where public.

Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap, since one statement can back several findings, and they show what the report kept, not how many clinicians agree.

The full SARON report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified HCP statements, each linked to the original. Get a complete report free to see what you get.

The open question for Medical Affairs

Which baseline disease states and post-induction patterns must be distinguished before discussing the applicability of SARON?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

By the numbers

free
Sources
  1. 41HCP commentary sources screened
  2. 30sources cited by verified HCP statements
People
  1. 41found in screened sources
  2. 40matched to verified clinician profiles
  3. 44voices cited in the report
Evidence
  1. 156verified HCP statements, each linked to its source
  2. 9findings
How to read these

Screened sources were retrieved for this trial. Cited sources back at least one verified HCP statement and include primary sources used for context. No count estimates how many clinicians hold a view. Size (Standard) is set by the 156 verified HCP statements.

What's inside

free
SectionItemsAccess
Findings with interpretation, counterviews and limits9Titles free
Detailed analysis11 sectionsPaid
Verified HCP statements with short source quotes and links156Paid
Trial aspects mapped11Free
Sources with links30Counts free
Speaker attribution for cited voices44Paid

Trial aspects

11 discussed · 0 no commentary · 0 incomplete
AspectStatementsSources
Primary endpoint: Overall Survival85
Secondary endpoints137
Population and setting2511
The comparison2812
Safety and tolerability65
Design and conduct3113
Biological selection, disease tempo and generalizability188
Completeness of treatment, staging and lesion-level coverage116
Systemic-treatment era, sequencing and repeated local intervention159
Clinical uptake, equipoise and access to comparative evidence2311
Interpretation of incomplete results and anticipated SARON impact2413

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Sources

free
ChannelScreenedCited
X threads3428
Podcasts42
YouTube30

max 7 / quarter

2020202120222023202420252026
screened citedper quarter, by source date
Screened window
Apr 14, 2019 → Oct 6, 2026
Cited window
Apr 14, 2019 → Sep 26, 2026
Retrieved
Oct 17, 2026

The trial

from ClinicalTrials.gov
Title
Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer. A Randomised Phase II Trial
Registry
NCT02417662
Study IDs
UCL/13/0594
Sponsor
University College, London
Collaborators
Cancer Research UK
Design
Not applicable · Interventional, randomized, parallel
Status
Active, not recruiting
Enrollment
140 actual
Start
2016-08-19 actual
Primary completion
2026-09 estimated
Primary endpoint
Overall Survival
Interventions
2 registered

Scope and limits

free

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

Known gaps
  • Discussion that does not name the trial may be missing from this edition.
  • Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
  • Out of scope: 1 passage in the reviewed sources discusses other trials or topics outside this report's scope; it is not part of this edition.
  • 12 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.
  • Further source limits apply, so some matching discussion may be missing.
  • The sources reviewed for this edition are not a representative sample of HCP opinion; neither source numbers nor repeated posts establish consensus.
  • Some potentially relevant posts and videos were unavailable, and searching mainly by trial names and identifiers may have missed unnamed or differently transcribed references.
  • Some passages may not have been fully assessed, so additional relevant qualifications or views may be absent.
  • Two comments relaying someone else's talk did not identify whose positions were being conveyed and cannot support attribution to a named clinician.
  • Several numerical study descriptions and results are clinicians' accounts of related trials, not independent extractions from complete trial reports.
  • The main SARON efficacy-results publication is not among the sources reviewed; anticipated effects on practice are expectations rather than observed implementation.
  • Anonymous panel responses are not assigned to people on a program or guest list. Professional credentials and identity confirmation are not equally available for all named authors.
  • Posts from different dates, settings or identically named accounts are not used to infer a change of mind or a longitudinal disagreement.
  • The two SARON thoracic sub-study safety posts use different severe-toxicity thresholds and do not establish late or whole-trial safety.
  • A full SARON protocol was not available in the reviewed material, limiting independent assessment of commentators' population and treatment comparisons.

How reports are built and checked: Methods.

Editions and corrections

free
v1.0.0Oct 17, 2026Current edition

Last checked for new commentary Oct 17, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Cite this report

Erudio Health. SARON (NCT02417662): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 17, 2026. https://www.erudio.com/reports/saron-nct02417662

For your AI agent

The same record as JSON or Markdown, or through the Erudio MCP server
shell
curl https://www.erudio.com/reports/saron-nct02417662.json
curl https://www.erudio.com/reports/saron-nct02417662.md

# MCP (https://mcp.erudio.com/mcp)
get_report_card({ "slug": "saron-02417662" })

release 911047668840ae30a75a252a0bf17dc0abb146955e0e65c13bd55ebc62da1232